Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T15:37:12.465Z.
Calculation as of: 2026-10-06T15:37:12.465Z.
Quote observation: 2026-10-06T15:34:49.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5f3696a2d024229c19dd1691f2f438020e28c75ff27c8cf4c9d796e14bd4a3b5
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$22.11M
EBITDA Yield
N/A
TTM Avg
24.06%
3Y Avg
27.42%
5Y Avg
27.42%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| iTonic Holdings Ltd. (ITOC) | $25.57M | N/A | N/A | N/A | N/A |
| ABVC BioPharma, Inc. (ABVC)vs › | $24.99M | N/A | 0.01% | 0.01% | 0.01% |
| Atossa Therapeutics, Inc. (ATOS)vs › | $24.74M | N/A | N/A | N/A | N/A |
| InspireMD, Inc. (NSPR)vs › | $26.75M | N/A | N/A | N/A | N/A |
| Kyntra Bio, Inc. (KYNB)vs › | $24.09M | N/A | 1.43% | 1.43% | 1.43% |
| Seres Therapeutics, Inc. (MCRB)vs › | $27.55M | N/A | N/A | N/A | N/A |
| aTyr Pharma, Inc. (ATYR)vs › | $28.65M | N/A | N/A | N/A | N/A |
| Aytu BioPharma, Inc. (AYTU)vs › | $22.11M | N/A | 24.06% | 27.42% | 27.42% |
| LeonaBio, Inc. (LONA)vs › | $21.87M | N/A | N/A | N/A | N/A |
| OneMedNet Corporation (ONMD)vs › | $29.77M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
